Daiichi Sankyo Company, Limited

Daiichi Sankyo Europe Gmbh

Bioinvent International Ab

Reimar Abraham

Keisuke Fukuchi

Thore Hettmann

Sabine Blum

Mauricio Redondo-Müller

Suguru Ueno

Toshiaki Ohtsuka

Ichiro Watanabe

Tanja Lange

Johannes Bange

Shinko Hayashi

The present invention relates to the amelioration of toxic effects that are caused by therapies aimed at FGFR4-inhibition. In particular, the invention relates to the combination of FGFR4 inhibitors and agents capable of reducing bile acid levels and to the use thereof in the treatment of diseases.

Combination of anti-FGFR4-antibody and bile acid sequestrant

To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; or -L-L-L- (the anti-HER3 antibody is connected to the terminal of L, the antitumor compound is connected to the carbonyl group of &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety or the C terminal of L, with the nitrogen atom of the amino group at position 1 as a connecting position). 

Anti-HER3 antibody-drug conjugate

The present invention relates to the medical use of antibodies against the FGF receptor 4 (FGFR4) combined with Sorafenib, in particular for the prevention or treatment of hyperproliferative diseases associated with FGFR expression, overexpression or hyperactivity.

Combination of human anti-FGFR4 antibody and Sorafenib

The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.

Human anti-FGFR4 antibody

Growing community of inventors

Munich, Germany

Reimar Abraham